radiopharmaceuticals
| 4 min read
Positive results for a radioligand therapy, a billion-dollar deal for a MASH drug, the Nobel Prize for immune system research, and more led the news this week.
| 4 min read
Big-ticket licensing, FDA shake-ups, and Alzheimer’s data led the news this week.
| 6 min read
Take a look into the making of the DDN Dialogues podcast episode: From warhead to cancer-killer, the quest for more actinium-225.
| 10+ min read
Actinium-225 is a radioactive isotope that kills cancer cells with a burst of alpha particles, but it was difficult to make enough of it — until now.
| 2 min read
License agreement allows POINT Biopharma to utilize Avacta’s pre|CISION platform for radiopharmaceuticals
Page 1 of 1 - 5 Total Items
